Design of Chemical Conjugate for Targeted Therapy of Multiple Sclerosis Based of Constant Fragment of Human Antibody Heavy Chain and Peptoid Analog of Autoantigen MOG35-55


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

Elimination of B cells producing autoantibodies to neuroantigens is considered as beneficial in the treatment of multiple sclerosis. Myelin oligodendrocyte glycoprotein (MOG) is a significant autoantigen in multiple sclerosis. It was shown that MOG-like peptoid AMogP3 can bind autoantibodies produced by pathological lymphocytes. We propose a structure of an innovative drug for targeted elimination of the pool of autoreactive B cells responsible for multiple sclerosis pathogenesis; this compound is a complex of peptoid AMogP3 with Fc fragment of human immunoglobulin. The obtained Fc-PEG-AMogP3 conjugate effectively interact with autoreactive antibodies, which attests to their high therapeutic potential.

Авторлар туралы

Y. Lomakin

M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry of Russian Academy of Sciences

Email: alexey.belogurov.jr@gmail.com
Ресей, Moscow

A. Stepanov

M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry of Russian Academy of Sciences

Email: alexey.belogurov.jr@gmail.com
Ресей, Moscow

D. Balabashin

M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry of Russian Academy of Sciences

Email: alexey.belogurov.jr@gmail.com
Ресей, Moscow

N. Ponomarenko

M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry of Russian Academy of Sciences

Email: alexey.belogurov.jr@gmail.com
Ресей, Moscow

I. Smirnov

M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry of Russian Academy of Sciences

Email: alexey.belogurov.jr@gmail.com
Ресей, Moscow

A. Belogurov

M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry of Russian Academy of Sciences

Хат алмасуға жауапты Автор.
Email: alexey.belogurov.jr@gmail.com
Ресей, Moscow


© Springer Science+Business Media New York, 2017

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>